Healthcare & Pharmaceuticals

The algorithms that make social media addictive have become powerful mechanisms for drug dealers
Eli Lilly, an Indianapolis based company, that has sold insulin products to diabetes patients since 1921, has quietly raised some U.S. prices 700 percent in the last 20 years by marketing so-called improved versions to consumers. Novo Nordisk, a Danish company, has also profited handsomely from this practice.
GlaxoSmithKline (GSK) has been accused of bribing doctors in China in order to boost sales. Chinese government officials say they have uncovered evidence of a bribery scheme involving 700 travel agencies who were used to funnel as much as three billion yuan ($480 million) in payments.
Scalpers are doing a booming business in key medical drugs by taking advantage of U.S. patients and hospitals when they are desperate for supplies from the poorly regulated $46 billion global contract-manufacturing industry.
As you already know, the governments of the western hemisphere and their corporate bosses are signing our names to the Free Trade Agreement of the Americas as we speak. This secret treaty's being made to destroy activist victories, privatize public services, and gut public safeguards; to roll back everything that 500 years of resistance has won.
AIDS activists are preparing rallies and demonstrations Thursday in several cities around the world to protest against global soft-drink giant Coca-Cola, which they charge must do more to help and treat its HIV-infected workers and their families in sub-Saharan Africa.
Two patents granted in the United States between 2000 and 2002 and another for which an application has been filed have put "maca", a high altitude Andean plant that is used by indigenous people in Peru, at the centre of a new battle against biopiracy, which involves the construction of an international network against the misappropriation of traditional knowledge.
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year.
Johnson & Johnson has been fined $1.2 billion in Arkansas over the sales of Risperdal, an antipsychotic drug. A circuit judge ruled that the company did not warn patients that the drug places elderly patients with dementia at an increased risk of major weight gain, possible diabetes and potential death.